PDF(Pubmed)
Abstract：
UNASSIGNED: Over the past decade, Corynebacterium striatum (C. striatum), an emerging multidrug-resistant (MDR) pathogen, has significantly challenged healthcare settings, especially those involving individuals with weakened immune systems. The rise of these superbugs necessitates innovative solutions.
UNASSIGNED: This study aimed to isolate and characterize bacteriophages targeting MDR-C. striatum. Utilizing 54 MDR-C. striatum isolates from a local hospital as target strains, samples were collected from restroom puddles for phage screening. Dot Plaque and Double-layer plate Assays were employed for screening.
UNASSIGNED: A novel temperate bacteriophage, named CSP1, was identified through a series of procedures, including purification, genome extraction, sequencing, and one-step growth curves. CSP1 possesses a 39,752 base pair circular double-stranded DNA genome with HK97-like structural proteins and potential for site-specific recombination. It represents a new species within the unclassified Caudoviricetes class, as supported by transmission electron microscopy, genomic evolutionary analysis, and collinearity studies. Notably, CSP1 infected and lysed 21 clinical MDR-C. striatum isolates, demonstrating a wide host range. The phage remained stable in conditions ranging from -40 to 55°C, pH 4 to 12, and in 0.9% NaCl buffer, showing no cytotoxicity.
UNASSIGNED: The identification of CSP1 as the first phage targeting clinical C. striatum strains opens new possibilities in bacteriophage therapy research, and the development of diagnostic and therapeutic tools against pathogenic bacteria.
UNASSIGNED: This study aimed to isolate and characterize bacteriophages targeting MDR-C. striatum. Utilizing 54 MDR-C. striatum isolates from a local hospital as target strains, samples were collected from restroom puddles for phage screening. Dot Plaque and Double-layer plate Assays were employed for screening.
UNASSIGNED: A novel temperate bacteriophage, named CSP1, was identified through a series of procedures, including purification, genome extraction, sequencing, and one-step growth curves. CSP1 possesses a 39,752 base pair circular double-stranded DNA genome with HK97-like structural proteins and potential for site-specific recombination. It represents a new species within the unclassified Caudoviricetes class, as supported by transmission electron microscopy, genomic evolutionary analysis, and collinearity studies. Notably, CSP1 infected and lysed 21 clinical MDR-C. striatum isolates, demonstrating a wide host range. The phage remained stable in conditions ranging from -40 to 55°C, pH 4 to 12, and in 0.9% NaCl buffer, showing no cytotoxicity.
UNASSIGNED: The identification of CSP1 as the first phage targeting clinical C. striatum strains opens new possibilities in bacteriophage therapy research, and the development of diagnostic and therapeutic tools against pathogenic bacteria.
摘要：
■在过去的十年中，纹状体棒状杆菌（C.纹状体),一种新兴的多药耐药（MDR）病原体，对医疗保健环境提出了重大挑战，尤其是那些免疫系统较弱的人。这些超级细菌的兴起需要创新的解决方案。
■本研究旨在分离和表征针对MDR-C的噬菌体。纹状体。利用54MDR-C从当地医院分离的纹状体作为目标菌株，从厕所水坑收集样品用于噬菌体筛选。点斑块和双层板测定用于筛选。
■一种新型温带噬菌体，命名为CSP1，是通过一系列程序识别的，包括净化，基因组提取，测序,测序和一步增长曲线。CSP1具有39,752个碱基对的环状双链DNA基因组，具有HK97样结构蛋白和位点特异性重组的潜力。它代表了未分类的Caudoviricetes类别中的一个新物种，在透射电子显微镜的支持下，基因组进化分析，和共线性研究。值得注意的是,CSP1感染和裂解21临床MDR-C。纹状体分离株,展示了广泛的主机范围。噬菌体在-40至55°C的条件下保持稳定，pH4至12，在0.9%NaCl缓冲液中，显示无细胞毒性。
■CS1作为第一个针对临床纹状体梭菌的噬菌体菌株的鉴定为噬菌体治疗研究开辟了新的可能性，以及开发针对致病菌的诊断和治疗工具。
■本研究旨在分离和表征针对MDR-C的噬菌体。纹状体。利用54MDR-C从当地医院分离的纹状体作为目标菌株，从厕所水坑收集样品用于噬菌体筛选。点斑块和双层板测定用于筛选。
■一种新型温带噬菌体，命名为CSP1，是通过一系列程序识别的，包括净化，基因组提取，测序,测序和一步增长曲线。CSP1具有39,752个碱基对的环状双链DNA基因组，具有HK97样结构蛋白和位点特异性重组的潜力。它代表了未分类的Caudoviricetes类别中的一个新物种，在透射电子显微镜的支持下，基因组进化分析，和共线性研究。值得注意的是,CSP1感染和裂解21临床MDR-C。纹状体分离株,展示了广泛的主机范围。噬菌体在-40至55°C的条件下保持稳定，pH4至12，在0.9%NaCl缓冲液中，显示无细胞毒性。
■CS1作为第一个针对临床纹状体梭菌的噬菌体菌株的鉴定为噬菌体治疗研究开辟了新的可能性，以及开发针对致病菌的诊断和治疗工具。
